Navigation Links
Immune Biosimilars Will Erode $10.8 Billion in Immune Biologics Brand Sales in 2019 Across the U.S., EU5 and Japan
Date:9/23/2010

BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biosimilar immune biologics will erode $10.8 billion in immune biologics brand sales in 2019 alone across the U.S., EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan. According to Biosimilars Advisory Service: Physician Perspectives on Pegylated Interferon-alpha and TNF-alpha Inhibitors in Immune and Infectious Disease, competition between branded and biosimilar TNF-alpha inhibitors and pressure to reduce costs through biosimilars use will contribute to a substantial erosion of brand sales.

Biosimilars' anticipated lower costs compared with branded biologics will be a major driver of their use among both U.S. and European gastroenterologists and rheumatologists. The majority of surveyed U.S. physicians in these specialties say that a policy that reduces or eliminates out-of-pocket costs for patients would significantly or moderately increase their prescribing of biosimilars. In France and Germany, where the cost burden on patients with serious disease is minimal, surveyed gastroenterologists and rheumatologists indicate biosimilars' potential to lower costs to their institutions and clinics will be a key driver of biosimilar use.

"While sales and costs associated with immune biologics, and TNF-alpha inhibitors in particular, make these agents an attractive target for manufacturers and payers, the extent to which biosimilars are able to reduce costs may be limited because of two main factors," said Decision Resources Analyst MaryEllen Klusacek, Ph.D. "First, high development and manufacturing costs for TNF-alpha inhibitors will likely prevent biosimilars in this class from being as steeply discounted as generic small molecule therapies. Second, our primary research suggests that gastroenterologists and rheumatologists will exhibit fairly conservative attitudes toward biosimilar uptake."

The Physician Perspectives on Pegylated Interferon-alpha and TNF-alpha Inhibitors in Immune and Infectious Disease module of the Biosimilars Advisory Service offers extensive primary research with U.S., French and German gastroenterologists and rheumatologists to highlight the key expectations that will drive or constrain biosimilar adoption.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision ResourcesDecision Resources, Inc.Lisa Osgood

Christopher Comfort781-993-2606

781-993-2597 losgood@dresources.com   ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. EUPROBIO 2008 Presentation to Highlight Latest Immune Research
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Peptimmune Presentations at Upcoming Events
9. Protein-printing technique gives snapshots of immune system defense
10. Visualizing asthma-causing immune cells at work
11. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from ... believe could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving ... to read it now. , Biomarkers are components in the blood, tissue ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):